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ABSTRACT
CEBPB, one of the CEBP family members, is a crucial
regulator of gene expression during innate immunity,
inflammatory responses and adipogenesis. In this
study, the EGF-induced increase of CEBPB mRNA
is shown to be coincident with the decrease of
COX-2 mRNA. We identified that all of the individual
CEBPB isoforms, LAP1, LAP2 and LIP, attenuate
EGF-induced COX-2 promoter activity. Although
increased sumoylation of both LAP1 and LAP2 is
observed during the lagging stage of EGF treatment,
only the sumoylated LAP1, but not the sumoylated
LAP2, is responsible for COX-2 gene repression. In
addition, EGF treatment can regulate the nucleocy-
toplasmic redistribution of HDAC4 and SUMO1. We
further demonstrated by loss-of- and gain-of-func-
tion approaches that HDAC4 can be a negative reg-
ulator while inactivating COX-2 transcription. The
sumoylation mutant LAP1, LAP1K174A, exhibits an
attenuated ability to interact with HDAC4, and
increased COX-2 promoter activity. Furthermore,
the in vivo DNA binding assay demonstrated that
LAP1K174A and CEBPDK120A, sumoylation-defec-
tive CEBPD mutants, attenuate the binding of
HDAC4 on the COX-2 promoter. In light of the
above, our data suggest that the suCEBPD
and suLAP1 are involved in the repression of COX-2
transcription through the recruitment of HDAC4.
INTRODUCTION
There are two known isoforms of cyclooxygenase (COX),
which is also known as prostaglandin H synthase
and prostaglandin endoperoxide synthase, COX-1 and
COX-2 (1,2). COX-1 functions as a housekeeping gene
and is constitutively expressed in most tissues. Conversely,
COX-2 is an inducible enzyme that is induced by cytokines
(3), growth factors (4), phorbol esters (5), endotoxins (6)
and oncogenes (7,8) in diﬀerent cell types. Previous studies
have shown that COX-2 is expressed in a large number of
human cancers and is involved in cancer development and
progression (9,10). Overexpression of COX-2 plays impor-
tant roles in hyperproliferation, transformation, cell
growth, invasion and metastasis of tumor cells. For the
transcriptional activation of the COX-2 gene, several tran-
scriptional activators, including nuclear factor-kappa B
(NF-kB) (11), CCAAT/enhancer-binding protein b
(CEBPB) (12), CEBP delta (CEBPD) (13,14), cyclic
AMP-responsive element binding protein (CREB) (15)
and activating protein 1 (AP1) (16), have been reported.
However, the participating components in the repression
of the COX-2 gene and mechanism have been less studied.
The CEBPs belong to a subfamily of the basic region of
leucine zipper (bZIP) transcription factors. Six members
have been identiﬁed in mammalian cells, including
CEBP alpha (CEBPA), CEBPB, CEBPD, CEBP
epsilon (CEBPE), CEBP gamma (CEBPG) and CEBP
zeta (CEBPZ). All CEBPs, except for CEBPZ, consist of
three structural domains: an N-terminal domain contain-
ing both positive and negative regulatory regions, a cano-
nical basic domain and a C-terminal leucine zipper
domain. The basic region binds to speciﬁc CCAAT
motifs located in CEBPs targeted gene promoter, whereas
the leucine zipper domain is responsible for heterodimer/
homodimer formation between various CEBP members
(17). CEBPB and CEBPD are involved in the regulation
of COX-2 transcription (12–14). The binding of CEBPB or
CEBPD on the CEBP or cyclic AMP-responsive element
(CRE) motifs of the human COX-2 promoter is increased
by inﬂammatory stimulation (18,19). Three variants of
CEBPBs have been detected in many cell types: a 46-
kDa full-length liver-enriched transcription-activating
protein (LAP1), a 42-kDa LAP2 and a 20-kDa
*To whom correspondence should be addressed. Tel: +886 6 2757575 31067; Fax: +886 6 2083663; Email: yumingw@mail.ncku.edu.tw
Correspondence may also be addressed to Wen-Chang Chang. Tel: +886 6 2353535 5496; Fax: +886 6 2749296; Email: wcchang@mail.ncku.edu.tw
 2008 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.liver-enriched transcription-inhibitory protein (LIP).
These variants are the result of an alternative translation
initiation due to a leaky ribosomal scanning mechanism
(20,21). LAP1 and LAP2 contain an N-terminal regula-
tory domain that is able to regulate the transcriptional
transactivation; however, their behavior is thought to be
diﬀerent within cells (22,23). Moreover, LIP is considered
to be a dominant-negative regulator of both LAP1/2 and
the remainder of the CEBP family members, because of
the lack of a transactivation domain. Recent studies have
shown that LAP1 not only functions as a transcriptional
activator but can also act as a transcriptional repressor to
inhibit gene transcription, such as peroxisome proliferator-
activated receptor beta /delta (PPAR /d) (24) and cyclin
D1 (25). Modiﬁcation of LAP1 by the small ubiquitin
modiﬁer (SUMO) family members, SUMO1 (26),
SUMO2 and SUMO3 (23), has been recently reported,
and this modiﬁcation has been proposed as important
for its inhibitory function. However, the chromatin-remo-
deling enzymes involved in the sumoylated LAP1
(suLAP1)-mediated transcriptional repression and target
genes are unclear.
Histone deacetylases (HDACs) participate in transcrip-
tional repression through the recruitment/interaction with
repressor/corepressor and the deacetylation of histones,
resulting in local modiﬁcation of chromatin structures.
In mammalian cells, there are two major categories of
HDACs classiﬁed according to the structures and homol-
ogy of the yeast counterparts (27). The widely expressed
class I HDACs, including HDAC1, 2, 3 and 8, are similar
to yeast RPD3 and are exclusively localized in the nuclei.
Class II HDACs are composed of HDAC4, 5, 6, 7, 9 and
10, which are expressed in a tissue-speciﬁc manner and
shuttle between the cytoplasm and nuclei in response to
external signaling (28). Both classes of HDACs can inter-
act with mSin3 and NuRD to form a large repressor com-
plex (29), which can be recruited by speciﬁc DNA-binding
factors to bind to the gene promoters (30). In addition,
other studies indicate that class II HDACs participate in
repression of gene expression in cell-speciﬁc development
not only through their deacetylase activity but also by
interacting with proteins and corepressors, such as CtBP
(31), NCoR/SMRT (32,33) and HP-1 (34). HDAC4 plays
a pivotal role in cell development through posttrans-
lational modiﬁcation of sumoylation. For example,
HDAC4 can interact with the myocyte enhancer factor-2
(MEF2) family, enhancing their sumoylation, then subse-
quently repressing MEF2-dependent transcription (35,36).
We previously reported that CEBPD modulates the
basal and epidermal growth factor (EGF)-induced COX-
2 transcription (14). Herein, we further demonstrated that
the increases of LAP1 and its sumoylation form are coin-
cident with the re-inactivation of the COX-2 gene expres-
sion upon long-term EGF treatment. Therefore, we
suggest that not only sumoylated CEBPD (suCEBPD)
but also suLAP1 may collaboratively participate in the
repression of COX-2 transcription. In addition, we
showed that EGF can regulate the nucleocytoplasmic
shuttling of HDAC4 and SUMO1 by immunoﬂuorescence
assay, and the time frame of CEBPBs induction coincides
with this reimporting of HDAC4 and SUMO1 into
the nuclei. Furthermore, the LAP1K174A shows a lower
HDAC4-interaction aﬃnity yet can enhance COX-2 pro-
moter activity compared with the wild-type LAP1. An
in vivo DNA-binding assay shows the spatial and temporal
binding activity of SUMO1, CEBPD, CEBPB and
HDAC4 on the COX-2 promoter followed EGF treat-
ment. Using the same in vivo DNA-binding approach,
we further demonstrated that the LAP1K174A and
CEBPDK120A attenuated the HDAC4-binding ability
to the COX-2 promoter. These results suggest that the
suLAP1 and suCEBPD both act as mediators in modulat-
ing HDAC4 recruitment on the COX-2 promoter.
MATERIALS AND METHODS
Materials
Human EGF was purchased from Peprotech (Rocky Hill,
NJ, USA). The COX-2, CEBPB, CEBPD, HDAC1,
HDAC4, glyceraldehydes 3-phosphate dehydrogenase
(GAPDH) and hemagglutinin [HA; for immunoprecipita-
tion (IP)] antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Antibodies
against HA (for western blot) were purchased from BM
(Boehringer, Mannheim, Germany) or Babco (Richmond,
CA, USA). Antibodies recognizing p300 were purchased
from Transduction Laboratories (Lexington, KY, USA).
Antibodies against SUMO1 were purchased from Zymed
Laboratories (South San Francisco, CA, USA).
Antibodies against SUMO2/3 were purchased from
Abcam (Cambridge, MA, USA). Lipofectamine 2000,
Dulbeco’s modiﬁed Eagle’s medium (DMEM), Opti-
MEM medium, the Trizol RNA extraction kit and
SuperScriptTM III were obtained from Invitrogen
(Carlsbad, CA, USA). The Arrest-In reagent was pur-
chased from Open Biosystems (Huntsville, AL, USA).
Monoclonal anti-HDAC1 antibodies, Protein A-agarose
and streptavidin–sepharose beads were purchased from
Upstate (Charlottesville, VA, USA). Fetal bovine serum
(FBS) was purchased from HyClone Laboratories (Logan,
UT, USA). The Taq DNA polymerases, the in vitro tran-
scription/translation kit and luciferase assay system were
from Promega (Madison, WI, USA). Expression plasmid
pcDNA3/HA was a gift from Dr Hsin-Fang Yang-Yen
(IMB, Academia Sinica, Taiwan). All oligonucleotides
for DNA aﬃnity precipitation assay (DAPA) and electro-
phoretic mobility shift assay (EMSA) were synthesized by
MDBio Inc. (Taipei, Taiwan). N-ethylmaleimide (NEM),
an inhibitor of SUMO proteases, was obtained from
Sigma (St Louis, MO, USA).
Plasmid construction
The numbering used to designate residues in CEBPB is
based on the human CEBPB sequence (NM_005194).
Expression vectors encoding HA-LAP1 (full-length C/
EBPB), HA-LAP2 (residues 24–345) and HA-LIP (resi-
dues 199–345) were constructed in pcDNA3/HA which
was ampliﬁed from the A431 cDNA with speciﬁc primers
as follows: LAP1F/BamHI: 50-GGATCCCAACGCCTG
GTGGCCTGG-30, LAP2F/BamHI: 50-GGATCCGAAG
TGGCCAACTTCTAC-30, LIPF/BamHI: 50-GGATCCG
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50-GAATTCCTAGCAGTGGCCGGAGGA-30. The fra-
gments were veriﬁed by sequencing and subcloned into
the pcDNA3/HA vector using BamHI and EcoRI. The
sumoylation mutants of HA/LAP1, HA/LAP1K174A,
and HA/LAP2, HA/LAP2K151A, were generated with a
QuikChang site-directed mutagenesis kit (Stratagene, CA,
USA). The reporters containing the COX-2 promoter
( 207/+49) and mutants were previously described (14).
Expression vectors encoding Flag-HDAC1 and Flag-
HDAC4 were generated by Dr Wen-Ming Yang (IMB,
National Chung-Hsing University, Taiwan).
Transfectionand reporter gene assay
Human epidermoid carcinoma A431 cells were grown in
DMEM supplemented with 10% FBS, 100mg/ml strepto-
mycin and 100 U/ml penicillin. In this series of experi-
ments, cells were cultured in serum-free condition with
or without treatment with 25ng/ml EGF. COX-2 reporter
and indicated expression vectors were cotransfected by
lipofection using the Arrest-In reagent or Lipofectamine
2000 according to the manufacturer’s instruction. The
total DNA amount for each transfection was matched
with pcDNA3 or related backbone vectors. After 6-h
transfection, cells were changed in fresh serum-free
DMEM medium and then were treated with EGF if neces-
sary for 15h.
Smallinterfering RNAs assay
Small interfering RNA (siRNA) pools for CEBPB and
scrambled control siRNA were purchased from Ambion
(Austin, TX, USA). The siRNA of HDAC4 was pre-
viously described (37,38) and purchased from Invitrogen
were (sense strands): HDAC4-1 (HD4-1), 50-AAUGUAC
GACGCCAAAGAUTT-30 and HDAC4-2 (HD4-2), 50-G
ACGGGCCAGUGGUCACUG-30. Cells were separately
transfected with CEBPB siRNA and control siRNA by
using Lipofectamine 2000. After 24h of transfection, the
lysates of transfectants were harvested after stimulation
with or without EGF for 5h for western blot with indi-
cated antibodies.
Invivo SUMO modification assayand Co-IPassay
A431 cells were transfected with the expression vectors
of HA/LAP1, HA/LAP1K174A, HA/LAP2 or HA/
LAP2K151A in the presence or absence of SUMO1
expression vectors by using the Arest-In reagent. After
24-h transfection, cells were washed twice with phosphate
buﬀered saline (PBS) containing 20mM N-ethylmaleimide
(NEM) and then harvested by scraping into 200mlo f
RIPA buﬀer containing protease inhibitors as previously
described (14). For the Co-IP assay, A431 were trans-
fected with 2mg of the indicated expression vectors by
using Arest-In reagent. After 24h, cells were harvested
with modiﬁed RIPA buﬀer plus protease and phosphatase
inhibitors which the details were previously described (14).
Five hundred micrograms of cell lysate was immunopre-
cipitated with 2mg of anti-HA antibodies in IP buﬀer in a
1:4 ratio of modiﬁed RIPA and IP buﬀer, 20mM HEPES
(pH 7.9), 2mM MgCl2, 0.2mM EDTA, 0.1mM KCl,
10% glycerol and 1mM dithiothreitol (DTT), under rota-
tion at 48C for 3h, and then plus protein A-agarose beads
were added for an additional 2h. Immunoprecipitated
beads were washed three times with washing buﬀer, 1 
PBS containing 0.1% IGEPAL CA-630. The immuno-
complexes were separated by 10% SDS–PAGE, followed
by western blot with anti-HA, anti-SUMO1 anti-SUMO2/
3 or anti-HDAC4 antibodies.
DNA affinityprecipitation assay
After 6h serum-free starvation, nuclear extracts of EGF-
treated A431 were harvested as indicated time courses.
DAPA was performed according to a previously described
method (14). Brieﬂy, the 200mg of lysates extracted from
each group were incubated with 2mg of biotinylated
C/EBP or CRE oligonucleotides in the presence of DNA
binding buﬀer. After 1h of incubation at 48C, 40mlo f
streptavidin–sepharose were added to the reaction mixture
and the incubation was continued for 1h. The complexes
were then precipitated by centrifugation and washed three
times with DNA binding buﬀer before they were resolved
by SDS–PAGE and subsequently analyzed by immuno-
blotting with speciﬁc antibodies. The sequences of 50-bio-
tinylated oligonucleotides were followed: CRE: 50-CACC
GGGCTTACGCAATTTTT-30 and CEBP: 50 -CAGTCA
TTTCGTCACATGGGC-30.
Electrophoretic mobility shiftassay
An EMSA was performedessentially as described byWang
et al. (14). Brieﬂy, the
32P-labeled probes (0.2–0.5ng) con-
taining the individual CEBP or CRE site were incubated
with 1mlo fin vitro-translated HA/LAP1, HA/LAP2 or
HA/LIP in speciﬁc binding buﬀer containing 10mM
Tris–HCl (pH 7.5), 50mM NaCl, 1mM DTT, 1mM
EDTA, 1mg of poly(dI-dC) and 10% glycerol. After
20min of incubation at room temperature, the reaction
mixtures were resolved in 5% native polyacrylamide gels
(acrylamide/bisacrylamide ratio, 30:1) at 48C, and the spe-
ciﬁc protein–DNA complexes were visualized by autora-
diography. The sequences of various oligonucleotides are
as described above.
Chromatin IP and re-chromatin IP assay
The chromatin IP (ChIP) assay was performed essentially
as described by Wang et al. (14). Brieﬂy, A431 cells were
treated with 1% formaldehyde for 15min. The cross-
linked chromatin was then prepared and sonicated to an
average size of 500bp. The DNA fragments were immu-
noprecipitated with antibodies speciﬁc to CEBPB,
CEBPD, SUMO1, HDAC1, HDAC4 or control rabbit
immunoglobulin G (IgG) at 48C overnight. After reversal
of the cross-linking, the immunoprecipitated chromatin
was ampliﬁed by primers related to speciﬁc regions of
the COX-2 genomic locus. For the re-ChIP assay, the
ﬁrst immune complex that had been washed twice with
washing buﬀer of 50mM Tris–HCl (pH 8.0), 0.1% SDS,
0.5% NP-40, 150mM NaCl and 2.5mM EDTA, and three
times with low-salt buﬀer of 10mM Tris–HCl (pH 8.0)
and 0.1mM EDTA, was then resolved in 10mM DTT
at 378C, further diluted in ChIP dilution buﬀer and then
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using the indicated antibodies. The primers were as fol-
lows: F-186, CTGGGTTTCCGATTTTCTCA and R-49,
GAGTTCCTGGACGTGCTCCT. The ampliﬁed DNA
products were resolved by agarose gel electrophoresis
and conﬁrmed by sequencing.
Immunofluoresce assay
A431 cells were seeded onto glass coverslips. Twenty-four
hours after reseeding, cells were starved in serum-free
medium for 8h prior to EGF treatment. Fixation was
performed in 4% formaldehyde in PBS at room tempera-
ture for 20min. After three times of washing by PBS, cells
were permeabilized with 1% Triton X-100 in PBS for
5min. Next, cells were preincubated with 0.5% Tween
20 in 0.5% BSA in PBS for 15min, blocked with 1%
BSA in PBS for 1h at room temperature and then incu-
bated for 1h at room temperature with following primary
antibodies diluted in 1% BSA in PBS: anti-HDAC4
(1:100). After washing with PBS for three times, cells
were incubated with the relative secondary antibodies
(Alexa Fluor 488 anti-rabbit 1:150) in 1% BSA/PBS for
1h at room temperature followed by washing in PBS.
Coversilps were then mounted with ProLong Gold anti-
fade reagent with 40-6-diamidino-2-phenylindole (DAPI)
(Invitrogen).
RESULTS
Expression ofCEBPBs is inducedafter long-term EGF
treatment inA431 cells
We previously reported that CEBPD can act as a bifunc-
tional regulator and is involved in both basal and EGF-
induced COX-2 expression (14). Since CEBPBs can form a
heterodimer with CEBPD and are implied to be involved
in the COX-2 gene regulation, we decided to investigate
whether the CEBPBs also participate in the EGF-regu-
lated COX-2 transcription. To elucidate the relationships
between CEBPD and three isoforms of CEBPB in EGF-
regulated COX-2 transcription, their expression patterns
were ﬁrst detected by RT–PCR assay and western blot.
Upon EGF treatment, the COX-2 expression was imme-
diately induced ( 1h), which is consistent with the
increase of CEBPD expression (Figure 1A and B, lane
1–6). This expression started to decrease after 3h of
EGF treatment. Interestingly, the induction of three iso-
forms of the CEBPB expression occurred in the long-term
EGF treatment, along with the decrease of COX-2 expres-
sion (Figure 1A and B, lane 4–8), although several studies
have suggested that LAP1 and LAP2 act as positive reg-
ulators, upregulating the COX-2 expression (12,39).
However, the lagging phase induction of LAP1 and
LAP2 conﬂicts with the positive regulation model of
COX-2 transcription. According to this observation, we
hypothesized that the slowly induced CEBPBs may play
diﬀerent roles in COX-2 gene regulation compared with
the immediately induced CEBPD.
CEBPB participation inrepression of EGF-induced
COX-2expression
To verify the repressive eﬀect of CEBPBs on COX-2
expression, a loss-of-function assay using the knockdown
approach was performed. Silencing of the three isoforms
of CEBPB reverses the COX-2 transcripts and protein
expression (Figure 2A). This suggests that the CEBPBs
indeed do play negative roles on COX-2 expression. As
mentioned above, LAP1 and LAP2 consist of transactiva-
tion and DNA binding/dimerization domains, whereas
LIP lacks the N-terminal transactivation domain. The
implication arising from this is that LIP can act as a
dominant-negative form protein, repressing transcrip-
tional activation through the formation of a heterodimer
with the rest of the C/EBP family members. The three
CEBPB variants are translated from one transcript, and
the 50-untranslated region (50-UTR) of CEBPB mRNA
plays a critical role in regulating the selected-translation
initiation of isoforms (20,40). To further dissect the eﬀect
of individual CEBPB isoforms on the regulation of the
COX-2 transcription, expression vectors bearing coding
cDNA of CEBPB isoforms, HA/LAP1, HA/LAP2 or
HA/LIP, without the 50-UTR were constructed for their
speciﬁc translation (Figure 2B). Compared with the con-
trol vectors upon EGF treatment, the well-characterized
negative regulator HA/LIP shows an inhibitory eﬀect on
the COX-2 promoter activity. Interestingly, both transfec-
tants of HA/LAP1 and HA/LAP2 show a consistent
repressive eﬀect in response to EGF treatment
(Figure 2C, right panel). In spite of this, the COX-2
Figure 1. Expression of COX-2 and CEBPs upon long-term EGF treat-
ment in A431 cells. (A) A431 cells were starved in serum-free medium
for 6h then treated with 25ng/ml of EGF. Total RNA was harvested at
the indicated times and an RT–PCR assay performed for the following
genes: COX-2, CEBPD, CEBPB and GAPDH.( B) The conditions were
the same as those described in (A); the cell lysates were harvested for
western blot and protein expressions of COX-2, CEBPD, CEBPB and
GAPDH were detected by speciﬁc antibodies.
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tants showing a repressive eﬀect on the COX-2 promoter
activity but not in the HA/LAP2 transfectants without the
EGF treatment (Figure 2C, left panel). These results sug-
gest that LAP1 and LIP, but not LAP2, have consistent
repressive roles regardless of EGF existence (Figure 2C).
Sumoylationof LAP1 isenhanced upon long-term EGF
treatment, andthe sumoylation mutant ofLAP1 attenuates
its repressive ability on theCOX-2 promoter
A previous study showed that the CEBP regulatory
domain motif (RDM) sequences are attachment sites for
SUMO1; furthermore, these SUMO1-conjugated sites,
LKAEP of LAP1- or LAP2-RDM domain, are necessary
and suﬃcient for the intrinsic inhibitory function of
RDMs (26). This report suggests the idea that the sumoy-
lated LAP1 and sumoylated LAP2 (suLAP2) may func-
tion as negative regulators in re-inactivation of the COX-2
expression upon long-term EGF treatment, which diﬀers
from the LIP-mediated repressive mechanism due to the
lack of transactivation domain. To verify whether
SUMO1-conjugated lysine residues are involved in the
regulation of COX-2 transcription, the sumoylation
mutants of LAP1 and LAP2 expression vectors, HA/
LAP1K174A and HA/LAP2K151A, were generated by
site-directed mutagenesis. First, an in vivo sumoylation
assay of LAP1 and LAP2 showed that increases of
suHA/LAP1 and suHA/LAP2 were observed when the
SUMO1 expression vector was cotransfected with expres-
sion vectors of HA/LAP1 or HA/LAP2 in A431 cells
(Figure 3A, compare lane 2 with lane 3, and lane 6 with
lane 7). This proved that SUMO1-conjugated sumoylation
of LAP1 and LAP2 does occur in A431 cells. Moreover, to
conﬁrm the SUMO1-conjugated speciﬁcity on the lysine
174 of LAP1 and the lysine 151 of LAP2, the HA/sumoy-
lation mutants of LAP1 and HA/LAP2, LAP1K174A and
HA/LAP2K151A, were recruited to perform the same
in vivo sumoylation assay. The SUMO1-conjugated pat-
terns were not visible in the cotransfectants of SUMO1
and HA/LAP1K174A or SUMO1 and HA/LAP2K151A
(Figure 3A, compare lane 4 with lane 5, and lane 8 with
lane 9). In addition, reciprocal IP assays were performed
to re-conﬁrm the in vivo SUMO1-cojugated LAP1. The
suHA/LAP1 is visible in the SUMO1 antibody-immuno-
precipition product of HA/LAP1 transfectant, but not
in the transfectants of HA/LAP1K174A or HA/LAP1
with SUMO1 siRNA (Figure 3B and Supplementary
Figure S4). These results indicate that the residues of
lysine 174 of LAP1 and lysine 151 of LAP2 are the
SUMO1-conjugated sites in A431 cells. Meanwhile, no
predictable super-shift band was observed in the HA/
LIP transfectants, indicating that it is not a SUMO1 sub-
strate (data not shown). Unlike transcriptional activation
of the COX-2 gene, transcriptional repression after long-
term EGF treatment has, up till now, been unexplored.
Therefore, the issue of whether the amounts of suLAP1
and suLAP2 are coincident with the re-inactivation of
COX-2 transcription needs to be examined. In considera-
tion of whether the long-term EGF treatment changes the
amounts of endogenous LAP1 and LAP2 in A431 cells,
the in vivo sumoylation assay was performed by exogen-
ously expressing the HA/LAP1 and HA/LAP2 to reveal
their sumoylated forms. The time frame for EGF-induced
suLAP1- and suLAP2-increases (Figure 3C) is consistent
with COX-2 transcription being re-inactivated (Figure 1).
This suggests that the suLAP1 and suLAP2 may partici-
pate in the re-inactivation of COX-2 transcription. We
further veriﬁed whether sumoylation of both LAP1 and
LAP2 function in the EGF-regulated COX-2 promoter
activity. Overexpression of HA/LAP1 or HA/LAP2
reduces the COX-2 promoter activity (Figure 2C), how-
ever, the overexpressed HA/LAP1K174A attenuates the
repressive activity of the COX-2 promoter as compared
with overexpression of HA/LAP1 (Figure 3D and
Supplementary Figure S1). In addition, there was no dif-
ference between the cotransfection of the COX-2 reporter
with the HA/LAP2 or the HA/LAP2K151A expression
vectors (data not shown). To further conﬁrm whether
the sumoylation of LAP1 indeed functions on the
COX-2 promoter, the CEBPB siRNA was cotransfected
Figure 2. CEBPBs participate in silencing COX-2 gene expression.
(A) A431 cells were transiently transfected with siRNA of CEBPB or a
scrambled control, C, for 24h then these transfectants were starved in
serum-free medium for 6h, followed by EGF treatment for 5h. Western
blot (left panel) and RT–PCR (right panel) were performed to detect
endogenous CEBPBs and COX-2 expressions. (B) Functional domains
of the transactivation domain (AD), regulatory (RD), basic (B) and leu-
cine-zipper domains (ZIP) are shown in the diagram. K174 and K151
represent the sumoylation sites of LAP1 and LAP2. (C) A431 cells were
transiently cotransfected with the COX-2 reporter and individual expres-
sion vectors of CEBPB isoforms with or without EGF treatment for 15h.
Data shown in left panel are representative results from three indepen-
dent experiments performed in triplicate. Luciferase activities are plotted
in arbitrary units. The results shown in right panel are averages from
three independent transfection assays. The average fold induction
(mean SD, n=3) of EGF-treated cells compared to control cells was
indicated. Statistical analysis was performed by Student’s t-test.
6070 Nucleic Acids Research, 2008, Vol. 36, No. 19with various indicated expression vectors in A431 cells.
Transfected CEBPB siRNA targeted the 30-UTR of
CEBPBs mRNA, silencing the endogenous CEBPBs
expression. Meanwhile, the CEBPB siRNA has no activity
for these cotransfected expression vectors containing only
the coding region of CEBPBs (Figure 3E, right panel).
Consistent with Figure 3D, LAP1K174A can reverse
the LAP1-mediated repression of COX-2 promoter
activity. However, LAP2K151A shows a consistent
COX-2 reporter activity compared with LAP2 upon
EGF treatment (Figure 3E and Supplementary
Figure S1). The results suggested that an intact lysine
174 of LAP1 is necessary for the repression of COX-2
promoter activity, and a sumoylation-independent
mechanism of LAP2 is involved in the LAP2-mediated
inactivation of COX-2 transcription.
Figure 3. SUMO1-conjugated lysine 174 of LAP1 plays a functional role in the regulation of COX-2 transcription. (A) Western blot was performed
with HA antibodies to detect A431 cell lysates from the transfectants of HA/LAP1, HA/LAP1K174, HA/LAP2 and HA/LAP2K151A with or
without SUMO1 expression vectors. The bold arrowhead indicates the positions of suHA/LAP1 and suHA/LAP2. (B) A431 cells were transfected
with expression vectors of HA/LAP1 or HA/LAP1K174A with or without SUMO1 siRNA for 24h. The lysates of transfectants were harvested, and
then for IP by SUMO1 antibody (Zymed). (C) The expression vectors of HA/LAP1 and HA/LAP2 were transiently transfected into A431 cells. After
6h of starvation, these transfectants were stimulated with EGF and harvested at indicated times. The exogenous expressions of HA/LAP1 and HA/
LAP2 proteins were detected using HA antibodies. (D) A431 cells were transfected with COX-2 reporter combined with the expression vectors of
HA/LAP1 or HA/LAP1K174A as indicated. Cell lysates were then prepared and analyzed for luciferase activity. The percentage of the repression
activity of transfectants was normalized to the control transfectants of COX-2 reporter and pCDNA3/HA vector.  P<0.05;   P<0.01;    P<0.001.
(E) A431 cells were transfected with COX-2 reporter and siRNA of CEBPB combined with the expression vectors of HA/LAP1 or HA/LAP1K174A
as indicated. Cell lysates were then prepared and analyzed for luciferase activity. Values of EGF-treated cells compared to control cells were
indicated. The percentage of the repression activity of transfectants (HA/LAP1, HA/LAP1K174A, HA/LAP2 and HA/LAP2K151A) was normalized
to the control transfectants of COX-2 reporter and siRNA of CEBPB (left panel). Western blot was performed with CEBPB antibodies to conﬁrm
the knockdown eﬃciency of CEBPB siRNA and verify the expression amounts of HA/LAP1, HA/LAP1K174A, HA/LAP2, HA/LAP2K151A and
LIP (right panel).
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andCRE motifs of theCOX-2 promoter
Our previous study showed that the CEBP and CRE
motifs (Figure 4A) both played critical roles in the
EGF-regulated COX-2 gene expression in A431 cells
(14). To verify whether CEBPBs can participate in
COX-2 transcription through these two motifs, a gel-
shift assay was carried out using individual in vitro-trans-
lated HA/CEBPB isoforms and labeled CEBP or CRE
probes. The three CEBPB isoforms bound directly to the
CEBP (Figure 4B, lanes 3–5) and CRE (Figure 4B, lanes
8–10) motifs. In addition, HDACs have been proven to be
recruited by sumoylated transcription factors, functioning
as corepressors to silence gene transcription (41). Our pre-
vious study implied that the CEBPD has the ability to
modulate the binding of chromatin remodeling enzymes,
histone acetyltransferases (HATs) or HDACs, through its
posttranslational modiﬁcation of acetylation or sumoyla-
tion. However, the components involved in the suCEBPD-
and suLAP1-mediated inactivation of the COX-2 gene are
uncertain. suCEBPD has been identiﬁed to contain higher
HDAC4-interactive activity by DAPA (Supplementary
Figure S2). To further determine the binding activity of
chromatin remodeling enzymes, such as p300, HDAC4
and CEBPBs on the CEBP or CRE motifs followed by
the EGF treatment, a DAPA was performed to show the
change of dynamic transcriptional complex. The pull-
down results of CEBP and CRE motifs show similar bind-
ing patterns (Figure 4C). Brieﬂy, the transient-increased
p300-binding activity is observed from 1h and returned to
the basal form after 4h of EGF treatment. Similar to the
lagging induction of CEBPBs, the apparent binding of
CEBPB isoforms was also detected from 4h and extended
to 12h upon EGF treatment. Interestingly, the binding
activity of HDAC4 is consistent with the CEBPBs binding
in the lagging stage of EGF treatment. These results sug-
gest that the lagging bindings of CEBPBs and HDAC4
may play a negative role in the regulation of COX-2 tran-
scription. Additionally, HDAC4 has been implicated in
interaction with SUMO1-conjugated substrates (36) and
the nucleocytoplasmic shuttling of HDAC4 is reportedly
controlled by signaling molecules (42,43). However, which
external stimulator can induce HDAC4 redistribution is
less studied. In our system, an equal distribution of
HDAC4 between nucleus and cytoplasm was observed
to pre-exist in nucleus during the EGF-starvation stage.
Importantly, the HDAC4 showed a lagging import from
4h and this extended to 8h upon EGF treatment
(Figure 5A, upper panel). On the other hand, the
SUMO1-conjugated proteins are predominant in the
nucleus, but transiently exported to the cytoplasm
during short-term EGF treatment up until 4h
(Figure 5A, lower panel). The Figure 5B further indicates
that HA/LAP1 is coexisting with endogenous HDAC4
and SUMO1 during the long-term EGF treatment.
Combining this information with that of Figure 3C and
Figure 4C, we suggest that the nuclear importation of
HDAC4 and SUMO1 coincides with the LAP1 induction
and the amount of sumoylated LAP1 during the inacti-
vated period of COX-2 gene transcription.
HDAC4, but notHDAC1, plays afunctionalrole
in silencing COX-2
HDAC4 is a SUMO E3 ligase and displays a transcrip-
tional repressor activity (32,36). However, its interactive
transcription factors and the detailed repressive mechan-
ism of transcriptional regulation are still less known. Since
the sumoylation of LAP1 plays a negative regulatory role
Figure 4. Bindings of CEBPBs parallel with HDAC4 binding upon long-term EGF treatment. (A) Schematic representation of the sequences of
CEBP and CRE motifs in this study. (B) In vitro translation of HA/CEBPD, HA/LAP1, HA/LAP2 and HA/LIP was performed, and the mixtures
with these products and DNA probes were subjected to a gel-shift (EMSA) assay as described in ‘Materials and methods section’. An arrowhead
indicates the retarded CEBPs-C/EBP or CEBPs-CRE complex. The in vitro-translated lysate without an expression vector is shown for the negative
control (lanes 1 and 6). (C) Nuclear extracts were harvested from A431 cells at the indicated times and were treated with or without EGF, then
incubated with biotin-labeled CRE or C/EBP oligonucleotides. The precipitated products were pulled down by streptavidin–sepharose and analyzed
by western blot with antibodies recognizing p300, HDAC4 or CEBPBs.
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HDAC4 plays a functional role in the suLAP1-mediated
repression of COX-2 transcription. Initially, a reporter
assay was performed by cotransfection of the COX-2
reporter with HDAC4 or HDAC1 expression vectors.
Interestingly, overexpression of HDAC4 attenuated
COX-2 promoter activity regardless of EGF existence
(Figure 6A); whereas, overexpression of HDAC1 showed
no eﬀect in A431 cells although it has been implied to be a
corepressor in the silencing of COX-2 transcription (44).
To further verify whether HDAC4 plays a functional role
through LAP1-binding with CEBP and CRE motifs, the
COX-2 reporters bearing the wild-type or the double
mutant of both CEBP and CRE motifs (mCEBP/CRE)
were cotransfected with HDAC4 expression vectors. Com-
pared to the HDAC4-mediated repressive eﬀect on the
wild-type COX-2 promoter, HDAC4 lost around 40% of
its repressive activity on the COX-2 reporter bearing the
CEBP/CRE mutant (Figure 6B and Supplementary
Figure S1). This suggests that the EGF-responsive ele-
ments, CEBP and CRE motifs, play a functional role in
response to the HDAC4-mediated repression of the COX-
2 promoter. Moreover, a knockdown approach was per-
formed to further conﬁrm the HDAC4-exerted repressive
eﬀect on COX-2 expression. Compared to the scrambled
control, the western blot (Figure 6C, left panel) and
RT–PCR assay (Figure 6C, right panel) show a consistent
result that the silence of HDAC4 enhances COX-2 expres-
sion regardless of EGF treatment. Furthermore, the spe-
ciﬁc siRNAs of CEBPB or HDAC4 were cotransfected
with the COX-2 reporter to detect whether this repressive
eﬀect occurred through the promoter regulation. The
silence of either CEBPB or HDAC4 can enhance both
the basal and EGF-induced COX-2 promoter activities
(Figure 6D). These results suggest that HDAC4 acts as a
repressor on COX-2 transcription through the CEBPs-
binding motifs, and that this repression not only functions
during the re-inactivation of the COX-2 gene in long-term
EGF treatment but also in the EGF-starved stage.
suLAP1 cooperates withHDAC4 to repressCOX-2
promoter activity
HDAC4 plays a suppressive role in the regulation of the
COX-2 promoter (Figure 6). suLAP1 is involved in the
negative regulation of COX-2 transcription (Figure 3D
and E). Further investigations were performed to deter-
mine whether suLAP1 collaborated with HDAC4 to
repress COX-2 promoter activity. To address this issue,
a reporter assay was performed by cotransfecting the
reporter of COX-2 promoter with various expression vec-
tors as indicated in Figure 7A and Supplementary
Figure S1. The cotransfected LAP1 and HDAC4 expres-
sion vectors showed a cooperatively repressive ability
against COX-2 promoter activity compared with transfec-
tion with the LAP1 expression vectors only (Figure 7A,
compare lane 2 with lane 4). This suggests that an increas-
ing amount of LAP1 can enhance HDAC4-mediated
repression of COX-2 transcription. In addition, the trans-
fection of LAP1K174A not only attenuates the LAP1-
mediated repression activity on the COX-2 reporter
(Figure 7A, compare lanes 1 and 2 with lanes 5 and 6),
but it also lost the HDAC4-mediated repressive activity on
the COX-2 reporter from 42% to 11% (Figure 7A, com-
pare lanes 2 and 4 with lanes 6 and 8). However, cotrans-
fection with HDAC1 expression vectors shows a
consistent COX-2 promoter activity (Figure 7A, compare
lanes 2 and 3 with lanes 6 and 7). This suggests that
suLAP1, at least in part, plays a functional role in
HDAC4-mediated repression of the COX-2 promoter.
Furthermore, whether LAP1 has a higher capability to
interact with HDAC4 than LAP1K174A was addressed
by a Co-IP assay with exogenously expressed HA/LAP1
or HA/LAP1K174A. Meanwhile, HA/LAP2, HA/
LAP2K151A and HA/LIP were recruited for comparison.
Figure 5. EGF treatment induces HDAC4 and SUMO1 nuclear
shuttling. (A) A431 cells were starved in serum-free medium for 6h
and then treated with EGF at indicated times. The cells were ﬁxed
in formaldehyde and stained with anti-HDAC4 and anti-SUMO1 anti-
bodies. The subcellular localization of HDAC4 (upper panel) and
SUMO1 (lower panel) were determined by immunoﬂuorescence micro-
scopy (green). DAPI was used to visualize nuclei distribution (blue).
(B) A431 cells were transiently transfected with HA/LAP1 expression
vector for 24h and then the transfectants were starved in serum-free
medium for 6h. Cells were ﬁxed and subjected to indirect immunoﬂuor-
escence staining. HA/LAP1 and endogenous HDAC4 (upper panel) or
SUMO1 (lower panel) were stained with monoclonal anti-HA (1:100,
red) and polyclonal anti-HDAC4 (1:100, green) or anti-SUMO1 (1:100,
green) antibodies, respectively. Coexistence of HA/LAP1 with HDAC4
or SUMO1 were showed in ‘Merge’.
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showed an obvious HDAC4-interactive activity, but the
HA/LAP1K174A-immunoprecipitated complex did not
(Figure 7B, right panel). However, the LAP2 and
LAP2K151A showed consistent and low HDAC4-interac-
tive activity (Supplementary Figure S3). HDAC4 is not
detectable in the HA/LIP precipitated immunocomplex
by anti-HA antibodies (data not shown). This implies
that the HDAC4-mediated repressive ability on the
COX-2 promoter is suLAP1-dependent but not LIP- and
suLAP2-dependent.
suCEBPD andsuLAP1 corporatelyfunction inthe
repression ofthe COX-2promoter activity
The transient COX-2 expression responds to external sti-
muli. Our previous study suggests that suCEBPD can act
as a negative regulator and may act through the recruit-
ment of HDACs to repress COX-2 transcription (14).
Herein, we further demonstrated that the suLAP1
negatively regulates COX-2 transcription. However, the
structure/type of in vivo binding of these molecules,
including CEBPD, CEBPB, SUMO1 and HDAC4, on
the COX-2 promoter under EGF treatment was unclear.
The ChIP assay, using extracts of indicated time courses
from the EGF-treated A431 cells, was performed to
further elucidate the scenario among SUMO1, CEBPD,
CEBPB and HDAC4. Consistent with our previous
study (14), the increasing binding of CEBPD was observed
within a short-term 1h of EGF treatment, and the binding
returned to the basal level upon EGF treatment for 12h.
However, increased CEBPB-binding activity was observed
from 3h and extended to 12h of EGF treatment. More
importantly, the HDAC4 binding pattern is consistent
with SUMO1-conjugated proteins; whereas, HDAC1
maintains consistent binding activity throughout the
time frame of EGF treatment (Figure 8A). To conﬁrm
whether CEBPD and CEBPB conjugated with SUMO1
and form a complex with HDAC4, the re-ChIP assay
was performed. In correlation with EGF-regulated
Figure 6. HDAC4, but not HDAC1, plays a negative role in regulating COX-2 transcription. (A) The COX-2 reporter was cotransfected with
HDAC1 or HDAC4 expression vectors for 15h in complete medium. Cell lysates were prepared for the luciferase assay. Three independent
experiments are represented by the statistical analysis. (B) Two COX-2 reporter vectors, pGC207/wt (WT) and pGC207/mCEBP/CRE (mCE/
mC), were cotransfected with HDAC4 expression vectors or empty vectors. Cell lysates were harvested for the luciferase assay. The repression
ratio was individually normalized with itself. (C and D) A431 cells were transfected with oligonucleotides-based siRNA of HDAC4 (HD4-1 or
HD4-2), CEBPB (CE-B) or the scrambled control (C). After 30h, these transfectants with or without EGF treatment were harvested to determine the
COX-2 expression by western blot analysis (left panel of C) and RT–PCR (right panel of C) or luciferase assay (D) (RD: relative density).
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or SUMO1-conjugated proteins including CEBPD and
CEBPB were observed in the long-term 12h of EGF treat-
ment, which was similar to the results with EGF-untreated
cells (Figure 8B). To further conﬁrm if CEBPDK120A
and LAP1K174A can attenuate the interaction of
HDAC4, the transient transfectants of HA/CEBPD,
HA/CEBPDK120A, HA/LAP1 or HA/LAP1K174A
were analyzed by the re-ChIP assays. The re-ChIP result
demonstrated that the sumoylation mutants of CEBPD
and LAP1 lost their HDAC4-binding capabilities
(Figure 8C). This in vivo DNA binding assay suggests
that the suCEBPD and suLAP1 have the potential to
interact with HDAC4 and inactivate COX-2 transcription.
Moreover, to clarify whether the suCEBPD and suLAP1
jointly regulated the inactivation of the COX-2 gene, the
reporter assay was carried out by cotransfection with the
COX-2 reporter and various CEBPs expression vectors as
indicated. Overexpressed CEBPD reversed HA/LAP1-
mediated repression of the COX-2 promoter activity
(Figure 8D, compare lane 4 with lane 6), and further
enhanced the HA/LAP1K174A-reversed COX-2 promoter
activity (Figure 8D, compare lane 6 with lane 7). More
importantly, an increase of COX-2 promoter activity
was observed when the cells were cotransfected with
LAP1K174A and CEBPDK120A expression vectors
(Figure 8D, compare lane 8 with lane 7). These results
suggest that suLAP1 and suCEBPD cooperate with each
other in the regulation of COX-2 promoter activity.
DISCUSSION
CEBPB is an important transcription factor involved in
cellular proliferation (45,46) and diﬀerentiation (47,48). It
is also involved in COX-2 gene regulation (12,19,39).
Herein, we were interested in the opposite biological phe-
nomenon of EGF-induced lagging CEBPBs expression
and the accompanying decrease of COX-2 transcription
(Figure 1). Our goal was to clarify whether CEBPBs
potentially play negative roles in COX-2 transcription.
All three individual CEBPBs negatively repressed the
COX-2 promoter via the exogenous expressions of
LAP1, LAP2 or LIP (Figure 2C). LIP is a well-studied
dominant negative regulator of CEBPs due to an absence
of the transactivation domain; however, the mechanism of
LAP1- and LAP2-mediated repression in transcriptional
regulation is unclear. LAP1 can be sumoylated on the
lysine 174 residue which was proven by an in vivo sumoy-
lation assay in A431 cells (Figures 3A, B and 7B and
Supplementary Figure S4). This is consistent with a pre-
vious report stating that LAP1 is a SUMO1 substrate (26).
The sumoylated form of LAP1 is coincident with the
steady increase of LAP1 upon long-term EGF treatment
(Figures 1B and 3C). Combining the LAP1K174A-
mediated de-repressive eﬀect (Figure 3D and E), we spec-
ulate that the increase of suLAP1 potentially plays a
repressive role in COX-2 transcription upon long-term
EGF treatment.
As corepressors, HDACs require speciﬁc transcription
factors to guide them and target DNA elements for their
precise regulatory functions. Several studies have pointed
out that HDAC1, HDAC3 and HDAC8 play functional
roles in COX-2 transcription (49–51). suCEBPD shows a
high aﬃnity in interaction with HDAC1, 3 and 4 but not
HDAC2 (52). We provided evidence to show that the wild-
type LAP1, and not the LAP1K174A, has a higher inter-
action aﬃnity with HDAC4 (Figure 7B). In addition, LIP
did not interact with HDAC4 in the Co-IP assay (data not
shown). HA/LAP2K151A does not reverse LAP2-
repressed COX-2 promoter activity and shows a consistent
HDAC4-binding activity with wild-type LAP2 (Figure 3E
and Supplementary Figure S3). The experimental results
suggest diﬀerent roles for each of the three isoforms of
CEBPB through interaction with HDAC4, although all
of them show a repressive eﬀect on COX-2 transcription.
LAP1 is not only a SUMO1 substrate (26) but also a
SUMO2/3 substrate (23). Most importantly, the lysine
174 of LAP1 is the major SUMO-conjugated site.
Our results demonstrate that the overexpression of
SUMO1 increases the SUMO1-conjugated HA/LAP1 in
A431 cells (Figure 3A). We also demonstrate that
Figure 7. HDAC4 is involved in the suLAP1-mediated repression of
COX-2 promoter activity. (A) The COX-2 reporter was cotransfected
with the indicated expression vectors. Cell lysates were harvested for
the luciferase activity assay. Reporter activities were normalized to the
control transfectant of the reporter and pCDNA3. (B) The wild-type
(WT) and sumoylation mutant (K174A) of HA/LAP1 were exogen-
ously expressed in A431 cells. HA antibodies were used for the Co-IP
assay. HDAC4, SUMO1 and HA antibodies were used for detection in
the western blot analysis.
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cipated complex but not in the HA/LAP1K174A-immuno-
precipated complex (Figure 3B, 7B and Supplementary
Figure S4). Furthermore, the knockdown of SUMO1
attenuates LAP1-mediated repression of the COX-2 pro-
moter (Supplementary Figure S5). These data suggest that
SUMO1-LAP1 can function in the repression of the COX-
2 promoter activity. However, we still could not rule out
the possibility that the SUMO2/3-conjugated LAP1 may
also participate in the regulation of COX-2 transcription
because the SUMO2/3 is also detectable in the HA/LAP1-
immunoprecipated complex but not the HA/LAP1K174A-
immunoprecipated complex (Supplementary Figure S6).
This issue requires further investigation. In addition,
Supplementary Figure S2 shows that the suCEBPD has a
higher HDAC4-interactive activity than wild-type
CEBPD. This provides explanation that the LAP1K174A
cannot fully recover HDAC4-exerted repressive activity
(Figure 3D, 3E and 7A), and is also consistent with the
result that the co-overexpression of CEBPK120A and
LAP1K174A can enhance COX-2 promoter activity
(Figure 8D). These results suggest that the suCEBPD
and suLAP1, but not suLAP2 or LIP, respond to
HDAC4-mediated repression of COX-2 transcription.
This result also provides evidence implying that the
CEBPD and LAP1 are both candidates in responding to
the HDAC4-mediated transcriptional regulation including
chromatin remodeling.
The CEBP and CRE motifs play critical functional roles
in the transcriptional regulation of the COX-2 gene
(4,14,16). CEBPD was shown to directly bind to these
two motifs by an in vitro DNA binding assay. This current
study demonstrates that CEBPBs can also bind to these
two sites (Figure 4B), suggesting the possibilities of
CEBPBs switching or coordination on the CEBP or
CRE motifs of the COX-2 promoter during the time-
dependent EGF treatment (Figure 9). Several papers
demonstrate that exogenously overexpressed CEBPD or
CEBPB are potential positive regulators on the COX-2
transcription. However, exogenously expressed CEBPD
has greater potential to be an acute responsive protein
than CEBPB in the induction of the COX-2 gene
Figure 8. suLAP1 and suCEBPD play a negative coordinating role in the transcriptional regulation of COX-2 gene, and were consistent with the
HDAC4 binding in the long-term EGF treatment. Sheared formaldehyde-cross-linked chromatin with or without EGF treatment from A431 cells
was immunoprecipitated with speciﬁc antibodies as indicated and the COX-2 promoter region was processed for PCR ampliﬁcation with speciﬁc
primers. As a positive control, PCR ampliﬁcation was also carried out with input DNA from chromatin before the IP step. The detailed procedures
of the ChIP (A) and re-ChIP (B) assay are described in ‘Materials and methods section’. (C) A431 cells were transfected with various expression
vectors as indicated for 24h. The re-ChIP assay was performed to determine the chromatin/protein complex of HDAC4 and CEBPD or LAP1 on
COX-2 promoter. The detailed procedures are described in ‘Materials and methods section’. (D) A431 cells were cotransfected with the COX-2
reporter and various expression vectors as indicated. Lysates of the transfectants were harvested for the luciferase assay.
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CEBPD- and CEBPB-mediated COX-2 transcription
needs to be further elucidated. In tumorigenesis, the over-
expression of LAP1/LAP2 has been reported in several
human tumors with the implication that it is correlated
with COX-2 expression, moreover leading to the conclu-
sion that CEBPB might be a crucial positive regulator in
COX-2 transcription. However, LIP draws less attention
because it comes from one transcript of the CEBPB gene
and is a strong repressor of COX-2 transcription. On the
other hand, our unpublished datademonstrates thatinduc-
tion of CEBPD expression is insensitive to external stimu-
lation in cancer cell lines because of hypermethylation of
the CEBPD promoter. Consequentially, this may result in
the inaccurate conclusion that CEBPD may potentially
be the most negative regulator just because its expression
does not match the increase of COX-2 expression in
tumors. Combining previous reports and our studies, we
speculated that the CEBPD serves as a bifunctional regu-
lator, at least in part, whereas LAP1/LAP2 may function
as repressors acting through spatial and temporal changes
to execute the switching of COX-2 transcription in
response to external stimuli (Figure 9). In cancer cells,
the overexpressed LAP1/LAP2 or de-sumoylated LAP1/
LAP2 can replace the silenced CEBPD and become a
potential activator of COX-2 transcription.
The overexpression of HDAC1 represses COX-2 pro-
moter activity in phorbol 12-myristate 13-acetate
(PMA)-treated HFb cells and in lipopolysaccharide
(LPS)-treated RAW 264.7 cells (44). CEBPB is suggested
to function in the gene repression of PPARb/d through a
HDAC1-mediated mechanism via a speciﬁc C/EBP-
responsive element (24). However, this current study
demonstrates that the exogenous overexpression of
HDAC1 alone has no eﬀect on COX-2 promoter activity
(Figure 6A) even with the cotransfected LAP1
(Figure 7A). A similar experiment was performed in our
ongoing study in which the overexpression of HDAC1 can
repress the PPARG2 promoter activity, participating in
the suCEBPD-mediated repression in HepG2 cells (52).
These results suggest that the HDAC1-mediated transcrip-
tional repression of genes may occur in cell type-depen-
dent or gene-speciﬁc manners (49). Class II HDACs show
a nucleocytoplasmic shuttling phenomenon through inter-
action with 14-3-3 protein (55,56). Under long-term EGF
treatment, the accumulation of HDAC4 shuttling in the
nucleus was observed. Interestingly, the SUMO1 or
SUMO1-conjugated proteins can be transiently exported
to the cytoplasm during the short-term EGF treatment.
Most importantly, the increasing amount of suLAP1 is
coincident with the SUMO1 re-importation and HDAC4
accumulation (Figure 5A). These observations are also
consistent with the ChIP and re-ChIP results that repre-
sent the in vivo transcription factor-binding pattern on the
COX-2 promoter in a time-dependent manner (Figure 8A
and B). Compared with LAP1, LAP2 is a shorter protein
lacking the N-terminal 23 amino acids in human. The
integrity of N-terminal LAP1 not only aﬀects the
SUMO2/3 conjugation, but is also essential for the speciﬁc
interaction of SWI/SNF complexes (23,57). Among the
CEBPB isoforms, the suLAP1 is the only eﬀecter involved
in the HDAC4-mediated repression of COX-2 transcrip-
tion. This implies that HDAC4 could be a functional dis-
tinguisher between the SUMO1-conjugated LAP1 and
LAP2, at least in COX-2 gene transcription. Additionally,
HDAC4 possesses the SUMO E3 ligase activity. This
raises an interesting issue of whether LAP1 is a HDAC4
substrate for its activity of SUMO E3 ligase. The over-
expressed HDAC4 transfectant shows a consistent sumoy-
lation of LAP1 (Supplementary Figure S7). This implies
that the sumoylation of LAP1 is in a HDAC4-indepen-
dent manner. Our data also demonstrate that the wild-
type LAP1 and CEBPD bear higher aﬃnities for
HDAC4 interaction than their sumoylation mutants.
Moreover, the PCR products of COX-2 promoter are
detectable in the CEBPD- or LAP1-re-ChIP samples
from the ChIP sample of HDAC4 (Figure 8C). These
results suggest that the suCEBPD and suLAP1 are able
to coordinate with HDAC4, and modulate COX-2 tran-
scription in A431 cells (Figure 9). However, the integra-
tion of the EGF-induced signaling pathway and the
HDAC4-nucleocytoplasmic shuttling remains unclear.
This precise study not only conﬁrms previous reports
suggesting that the CEBPB could be a repressor but also
dissects the function of CEBPB isoforms in COX-2 tran-
scription upon the long-term EGF treatment-induced
re-inactivation and the EGF-starved stage. HDAC4
plays a role as a kinetic regulator in a time-dependent
manner to coordinate the regulation of the COX-2 gene.
suCEBPD, on the lysine 120 residue, and suLAP1, on the
Figure 9. The involvement of CEBPD and LAP1 in the EGF-regulated
COX-2 transcription. In the resting stage or starving stage, suCEBPD
and suLAP1 could bind to the CRE and CEBP motifs of COX-2
promoter and interact with nuclear HDAC4 to form a repressive com-
plex. In the early 1–3h of EGF treatment, the instantly induced non-
sumoylation of CEBPD can be positive regulators that replace the
suCEBPD and suLAP1. This replacement will increase the p300 bind-
ing and form an intact initiation of the activation complex to stimulate
COX-2 transcription. After 3h of EGF treatment, combination of
decreased binding of nonsuCEBPD and p300, with the increased bind-
ing of suLAP1, suCEBPD and increased importation of HDAC4 will
re-inactivate COX-2 transcription through the new formation of the
HDAC4/suCEBPD/suLAP1 complex.
Nucleic Acids Research, 2008, Vol. 36, No. 19 6077lysine 174 residue, are involved in the interaction of
HDAC4, and function in the HDAC4-mediated repres-
sion of COX-2 transcription.
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